A detailed history of Wedmont Private Capital transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wedmont Private Capital holds 3,249 shares of VRTX stock, worth $1.63 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
3,249
Previous 3,184 2.04%
Holding current value
$1.63 Million
Previous $1.49 Million 1.27%
% of portfolio
0.09%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$460.0 - $505.78 $29,900 - $32,875
65 Added 2.04%
3,249 $1.51 Million
Q2 2024

Jul 15, 2024

BUY
$392.81 - $485.53 $49,494 - $61,176
126 Added 4.12%
3,184 $1.49 Million
Q1 2024

Apr 10, 2024

BUY
$407.69 - $446.08 $86,837 - $95,015
213 Added 7.49%
3,058 $1.28 Million
Q4 2023

Jan 09, 2024

BUY
$343.0 - $410.68 $117,306 - $140,452
342 Added 13.66%
2,845 $1.16 Million
Q3 2023

Oct 10, 2023

BUY
$338.18 - $362.46 $79,472 - $85,178
235 Added 10.36%
2,503 $870,000
Q2 2023

Jul 17, 2023

BUY
$314.42 - $351.91 $153,751 - $172,083
489 Added 27.49%
2,268 $798,000
Q1 2023

Apr 11, 2023

SELL
$283.23 - $323.1 $37,103 - $42,326
-131 Reduced 6.86%
1,779 $560,000
Q4 2022

Jan 09, 2023

BUY
$285.76 - $321.48 $88,014 - $99,015
308 Added 19.23%
1,910 $0
Q3 2022

Oct 03, 2022

BUY
$273.83 - $305.53 $90,363 - $100,824
330 Added 25.94%
1,602 $464,000
Q2 2022

Jul 11, 2022

BUY
$234.96 - $292.55 $72,837 - $90,690
310 Added 32.22%
1,272 $358,000
Q1 2022

Apr 05, 2022

BUY
$221.42 - $260.97 $213,006 - $251,053
962 New
962 $258,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Wedmont Private Capital Portfolio

Follow Wedmont Private Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedmont Private Capital, based on Form 13F filings with the SEC.

News

Stay updated on Wedmont Private Capital with notifications on news.